dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
Published 4 years ago • 345 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
3:13
dr. herzog on the fda approval of olaparib/bevacizumab as frontline maintenance in ovarian cancer
-
6:01
olaparib and bevacizumab: on the horizon for treating ovarian cancer
-
7:56
maintenance therapy in ovarian cancer
-
2:27
the paola-1 study: olaparib and bevacizumab for ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
1:25
olaparib in ovarian cancer
-
1:05
dr. essel discusses long-term bevacizumab in ovarian cancer
-
7:09
biomarker-driven frontline ovarian cancer treatment
-
4:54
impact of solo-1 on advanced ovarian cancer management
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer
-
5:53
adverse-effect profiles of parp inhibitors in ovarian cancer
-
4:23
comment: parp inhibitor olaparib plus bevacizumab in women with ovarian cancer
-
5:25
solo-1: frontline olaparib maintenance therapy in ovarian cancer
-
9:49
paola-1 phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
-
1:18
dr. backes on treatment selection with parp inhibitors in ovarian cancer
-
1:13
final os results from paola-1 evaluating 1l maintenance olaparib plus bevacizumab
-
1:30
dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc